Search 

The Multifunctional pipette is tool for fast localized solution delivery for bioscientists.

It is comprised of a pneumatic control unit, an interfacing holder and the disposable pipette.

In combination with conventional micromanipulation apparatus, a small 100 micron  virtual flow chamber can be free positioned within a sample.

​Utilizing hydrodynamic confinement, the delivered solution can be localized and rapidly switched without contaminating the sample; enabling large numbers of experiments and parameters to be screened on a single sample dish.

Automation and screening can be achieved through scripting protocols.

Labview and Matlab libraries are now available.

​

Organ and cell transplantations are currently the standard therapy for end-stage organ failure. However, allograft rejections, monitoring of optimal immunosuppression, and shortage of donor organs, are major problems encountered in the field.

The Sahlgrenska Transplantation Unit which is the largest organ transplant clinic in Sweden, has in 2008 made strategic recruitments of a multi-disciplinary team of highly qualified and experienced transplant surgeons and research scientists who, in close collaboration with the clinical transplantation programs, have established the Laboratory for Transplantation and Regenerative Medicine at the Sahlgrenska Academy.

The various projects we present concern:

1) Prevention of allograft rejection by improved donor-recipient selection.
2) Solve organ shortage using two new strategies - namely to avoid allograft rejection by the creation of non-immunogenic scaffolds both for allo- and xenograft rejection and the generation of endothelial and hepatic progenitor cells for transplantation.

We have introduced new specific methods to characterize and assess the importance of alloantibodies, both HLA and non-HLA-specific, as a risk factor for graft rejections. Our efforts aiming at understanding the molecular basis of xenograft rejection will continue, but will focus on delineating the immunogenicity of vascular scaffolds (vessels and heart valves) derived from pig. Such scaffolds may constitute an on-demand source of templates for tissue-engineered vascular grafts.
We have succeeded in isolating human endothelial and liver progenitor cells that not only self-proliferate ex vivo, but also functionally repopulate the damaged organs/tissues of mice with acutely injured organs.
Recently, we have been pioneering in the field of tissue-engineering, creating biocompatible blood vessels for clinical use. Experimental injury models will be used to study mechanisms of human progenitor cell migration, integration and engraftment in the injured tissues. Deciphering mechanisms of stem cell migration and engraftment will provide clinically relevant information that will make tissue repopulation with stem cells more feasible clinically. Tissue-engineered biocompatible tissues or organs using recipient’s autologous stem cells will be a major breakthrough in regenerative medicine and may help solve the organ shortage.

GU Holding is a company owned by the Swedish government. Its mission is to provide funds and business competence for new companies to ensure growth of value and development of companies based on top-notch academic competence and research within University of Gothenburg.

The business concept consists of supplying project and start-up capital together with business competency to add value to and efficiently develop new businesses based on academic leading edge competency and research results. The aim is to create successful growth companies. All projects must be commercially viable, and business ideas and inventions must meet high standards.

GU Holding's mission is to contribute to the development of University of Gothenburg, its staff as well as the whole of the Västra Götaland region. There is close cooperation between the university, including all pursued disciplines, and its various bodies dealing with commercialisation, such as GU Research and Innovation Services.

GU Holding works together with Research and innovationservice at University of Gothenburg. Further, GU Holding has close contact with other innovation actors, such as The Innovation Bridge, Sahlgrenska Science Park, Vinnova, Innovationskontor Väst, Västra Götaland Region and Tillväxtverket as well as business entrepreneurs, private actors within trade and industry or on the capital market, for instance highly esteemed venture capitalists.

The portfolio of GU Holding consists of 33 newly build companies and 14 business projects in many different areas.

GU Holding has invested in pain relief, speaking computers, customized back-in counters, security, oyster farming, a cure for kidney cancer and fish feed ingredient to name a few.

Company: LipUm AB, Umeå, Sweden (Susanne Lindquist, Olle Hernell and Lennart Lundberg)

 LipUm AB´s goal is to develop a novel biological anti-inflammatory therapy with the protein BSSL (Bile Salt-Stimulated Lipase) as target.

At Medicon Village we want to create an environment where research, innovation and entrepreneurship work together to create value for people’s health and wellbeing. Together with the medical research centres Biomedical Centre (BMC) in Lund and the Clinical Research Centre (CRC) in Malmö, as well as the developing research facilities ESS and the MAX IV laboratory, Medicon Village is establishing an infrastructure of world class and thus providing a huge lift to, and enhancing the attractiveness of, the entire region. The total area available for letting within Medicon Village amounts to around 80,000 m2, of which laboratories account for about 30,000 m2. It is estimated that activities involving the employment of around 500 persons will be established within the facility during the initial phase. Later on, when the plan has been fully executed, more than 1,000 persons will be involved in the activities at Medicon Village.

Marketing and Development of medtech products

Redoxis is a Swedish company which main competence is target validation and preclinical development of novel therapies for autoimmune diseases. Redoxis focus both on own target discovery research and professional CRO services on preclinical drug and target evaluation in animal models. Our main interest and knowledge is within rheumatoid arthritis (RA) and multiple sclerosis (MS) and we have several years of expertise of animal models for these diseases. We offer services regarding evaluation of novel drugs and therapeutic targets both in vitro, ex vivo and in vivo in animal models and we can assist in design, performance and interpretation of the results from the experiments. Our model systems are well validated and as a small company can offer flexible study design through communication with our sponsors. 

Redoxis drug development project is characterized by protected small molecules targeting target of immunological relevance that are regulated by Redoxis stimulation and of importance in CD4 T cell receptor signaling immune responses. Of primary focus are autoimmune disorders like the orphan disease Guillain-Barrés Syndrome (GBS), Multiple Sclerosis (MS) and Rheumatoid Arthritis (RA).

Because of restricted inherent capacity of regeneration and healing, the restoration of function to damaged heart remains formidable contest. In our laboratory we are trying to develop protocols for regenerating pig heart tissues by first stripping of cells and then repopulating the acellular scaffold with human stem cells. Such tissue engineered hearts may be potentially used for transplantation in future.